Efficacy and safety of DPL500 combined with tacrolimus ointment in the treatment of type Ⅰ rosacea

Objective To evaluate the efficacy and safety of DPL500 combined with tacrolimus ointment in the treatment of type Ⅰ rosacea. Methods A total of 80 patients with type Ⅰ rosacea were enrolled at the Foresea Life Insurance Guangzhou General Hospital from October 2020 to September 2022, and randomly di...

Full description

Saved in:
Bibliographic Details
Main Authors: Danbin SU (Author), Qilin LI (Author), Yingyun REN (Author), Yahui LIU (Author), Jiaping LI (Author)
Format: Book
Published: editoiral office of Journal of Diagnosis and Therapy on Dermato-venereology, 2024-01-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_b4e5f95b047e4f6e8f9e743d63f7a67e
042 |a dc 
100 1 0 |a Danbin SU  |e author 
700 1 0 |a Qilin LI  |e author 
700 1 0 |a Yingyun REN  |e author 
700 1 0 |a Yahui LIU  |e author 
700 1 0 |a Jiaping LI  |e author 
245 0 0 |a Efficacy and safety of DPL500 combined with tacrolimus ointment in the treatment of type Ⅰ rosacea 
260 |b editoiral office of Journal of Diagnosis and Therapy on Dermato-venereology,   |c 2024-01-01T00:00:00Z. 
500 |a 1674-8468 
500 |a 10.3969/j.issn.1674-8468.2024.01.002 
520 |a Objective To evaluate the efficacy and safety of DPL500 combined with tacrolimus ointment in the treatment of type Ⅰ rosacea. Methods A total of 80 patients with type Ⅰ rosacea were enrolled at the Foresea Life Insurance Guangzhou General Hospital from October 2020 to September 2022, and randomly divided into the observation and control groups, 40 cases per group. The observation group was treated with DPL500 once a month and 0.1% tacrolimus ointment twice-daily for 3 months, while the control group was treated with 0.1% tacrolimus ointment alone. The efficacy and safety were compared between the two groups. Results Following the treatment, the total effective rate was higher in the observation group than in the controls (97.50% vs. 80.00%, χ2=4.51,P<0.05). More rapid improvements in skin flushing, telangiectasia, erythema and skin sensitivity were observed in the observation group compared to the controls (P<0.05). Although the baseline subjective and objective scores did not differ significantly between the two groups (P>0.05), both subjective and objective scores in the observation group were significantly lower than that in the controls after 30-, 60- and 90-day treatment (P<0.05). However, adverse reactions were comparable between the two groups (χ2=0.18,P=0.672). Conclusions DPL500 combined with tacrolimus ointment is effective and safe in the treatment of type Ⅰ rosacea. It can quickly improve the facial symptoms. 
546 |a ZH 
690 |a dpl500 
690 |a tacrolimus ointment 
690 |a type ⅰ rosacea 
690 |a clinical efficacy 
690 |a safety 
690 |a Dermatology 
690 |a RL1-803 
655 7 |a article  |2 local 
786 0 |n Pifu-xingbing zhenliaoxue zazhi, Vol 31, Iss 1, Pp 9-14 (2024) 
787 0 |n http://pfxbzlx.gdvdc.com/EN/10.3969/j.issn.1674-8468.2024.01.002 
787 0 |n https://doaj.org/toc/1674-8468 
856 4 1 |u https://doaj.org/article/b4e5f95b047e4f6e8f9e743d63f7a67e  |z Connect to this object online.